307983-31-9

Basic information

• Product Name: GRA Ex-25
• Synonyms: GRA Ex-25;B-Alanine, N-[4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]methyl]benzoyl]-
• CAS NO: 307983-31-9
• Molecular Formula: C29H36F3N3O5
• Molecular Weight: 563.613
• Mol File: 307983-31-9.mol
• Article Data: 3

Chemical Properties

• Melting Point: 152-154 °C
• Boiling Point: 726.3±60.0 °C(Predicted)
• Appearance: /
• Density: 1.28±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 4.29±0.10(Predicted)
• CAS DataBase Reference: GRA Ex-25(CAS DataBase Reference)
• NIST Chemistry Reference: GRA Ex-25(307983-31-9)
• EPA Substance Registry System: GRA Ex-25(307983-31-9)

Safety Data

• Hazardous Substances Data: 307983-31-9(Hazardous Substances Data)

Usage

General Description

GRA Ex-25 is a proprietary blend of chemicals designed to improve the performance and effectiveness of gravel pack completions in oil and gas wells. It is a unique formulation that includes a combination of surfactants, viscosifiers, and fluid loss additives to optimize the packing of gravel in the annular space between the wellbore and the formation. This chemical blend is specifically formulated to enhance the stability and packing efficiency of the gravel, ensuring a more secure and effective barrier to prevent sand production and maintain well integrity. GRA Ex-25 is also compatible with a wide range of base fluids and can be easily customized to meet the specific requirements of different well conditions and applications.

Upstream product

• 307989-04-4 3-{4-[1-(cis-4-tert-Butylcyclohexyl)-3-(4-trifluoromethoxyphenyl)ureidomethyl]-benzoylamino}propionic acid ethyl ester 
• 35037-73-1 1-isocyanato-4-trifluoromethoxy-benzene 
• 5400-88-4 4-tert-butylcyclohexylamine 
• 42823-24-5 4-(trifluoromethoxy)aniline hydrochloride 
• 1571-08-0 methyl 4-formylbenzoate 
• 307989-24-8 trans-4-[(4-tert-butylcyclohexylimino)methyl]benzoic acid methyl ester 
• 307989-02-2 trans-3-{4-[1-(4-tert-butylcyclohexyl)-3-(4-trifluoromethoxyphenyl)ureidomethyl]benzoylamino}propionic acid ethyl ester 
• 307983-40-0 trans-3-{4-[1-(4-tert-butylcyclohexyl)-3-(4-trifluoromethoxyphenyl)ureidomethyl]benzoylamino}propionic acid methyl ester 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 307989-03-3 cis-4-[1-(4-tert-butylcyclohexyl)-3-(4-trifluoromethoxyphenyl)ureidomethyl]benzoic acid 
• 307988-99-4 cis-4-[(4-tert-butylcyclohexylamino)methyl]benzoic acid methyl ester 
• 307989-01-1 trans-4-[1-(4-tert-butylcyclohexyl)-3-(4-trifluoromethoxyphenyl)ureidomethyl]benzoic acid 
• 307989-27-1 3-(4-{[tert-butoxycarbonyl-(4-tert-butyl-cyclohexyl)-amino]-methyl}-benzoylamino)-propionic acid methyl ester 
• 307989-28-2 3-{4-[(4-tert-butyl-cyclohexylamino)-methyl]-benzoylamino}-propionic acid methyl ester 

Relevant articles and documents

New β-alanine derivatives are orally available glucagon receptor antagonists

A weak human glucagon receptor antagonist with an IC50 of 7 μM was initially found by screening of libraries originally targeted to mimic the binding of the glucagon-like peptide (GLP-1) hormone to its receptor. Optimization of this hit for binding affinity for the glucagon receptor led to ligands with affinity in the nanomolar range. In addition to receptor binding, optimization efforts were made to stabilize the molecules against fast metabolic turnover. A potent antagonist of the human human glucagon receptor was obtained that had 17% oral availability in rats with a plasma half-life of 90 min. The major metabolites of this lead were identified and used to further optimize this series with respect to pharmacokinetic properties. This final optimization led to a potent glucagon antagonist that was orally available in rats and dogs and was efficacious in lowering blood glucose levels in a diabetic animal model.

Glucagon antagonists/inverse agonists

Disclosed is a novel class of compounds of formula (I) wherein V, A, Y, Z, R1, E, X and D are as defined in the specification. These compounds act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor, the compounds are suitable for treating or preventing glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.